Center for Personalized Diagnostics
Dr. David Roth, Director of the Precision Medicine Program at Penn, explains precision medicine and the Center for Personalized Diagnostics.
The Center for Personalized Diagnostics (CPD) is a joint initiative between Penn Medicine's Department of Pathology and Laboratory Medicine and the Abramson Cancer Center to support precision medicine at Penn.
The CPD aims to uncover genetic mutations within a patient's own cancer that can allow for a more targeted and personalized "precision" treatment strategy.
By integrating Molecular Genetics, Pathology Informatics, and Genomic Pathology for precision-medicine diagnoses, the CPD can help physicians provide an appropriate and individualized treatment plan for their patients.
Precision genomic diagnostics can identify patients who might benefit from current, often cutting-edge therapies, while sparing those who do not have a particular genetic signature from the costs and side effects of certain treatments.
Most importantly perhaps, precision medicine can significantly reduce the time conventional diagnostic approaches require, allowing patients and their loved ones to make informed decisions – when time matters most.
For Patients and Caregivers
Each cancer responds differently to treatment. Knowing the makeup of your cancer can help determine a better and more exact treatment.
- Learn how researchers at the CPD are working to understand how best to treat your cancer at a genetic level.
- Learn how to talk to your doctor about precision medicine and genomic testing.
For Physicians and Researchers
The Center for Personalized Diagnostics offers physicians the highest volume of genome testing in the region, with more than 4,000 clinical and research samples to date. More research means stronger, actionable results for your patients.
Genomic sequencing reports provided by the CPD are specifically geared toward actionable knowledge for clinicians. The reports focus on normal or abnormal gene information and provide interpretation, comments, and references for disease-associated mutations or variants of uncertain significance.
Learn more about the benefits of ordering a personalized diagnostic test, the different gene panels CPD offers analysis for, and how to request a test for your patients today.
CPD by the Numbers
Since the launch of operations in February 2013, the CPD has performed more than 4,000 advanced diagnostics on patients, representing a wide range of cancers: 24% lung cancer, 21% gastrointestinal cancers, 15% acute myeloid leukemia, 13% brain cancers, 8% melanoma, 19% other cancers (breast, thyroid, other).
CPD at Penn Medicine
- Highest volume of testing in the region with more than 4,000 tests
- Fast turnaround time (avg. 10-14 days) with review by subspecialized pathologists
- Actionable findings: 75% of tests could have impact on diagnosis, prognosis, or therapeutic decisions
- User-friendly reports with a focus on actionable information
- Offering four precise cancer gene-sequencing panels
- Custom-developed bioinformatics for higher sensitivity and accuracy
- Clinical and translational expertise and guidance of a major academic medical center
- Assessments of results by multidisciplinary experts (tumor boards and pathologists)
Questions & Information: